Both drugs were similar in terms of safety, although there was a nonsignificant trend toward a higher incidence of serious side effects with infliximab. 82 Kruh et al published the largest single-center retrospective, interventional, noncomparative cohort study evaluating the safety and efficacy of infliximab in various types of uveitis that failed to respond to other treatments.
1
—
—